Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer

详细信息    查看全文

• 作者：Prasanna Rajagopalan ; Khalid A. Alahmari…
• 关键词：Arylidene ; Indan ; one ; FXY ; 1 ; Apoptosis ; Cell cycle ; Akt ; Lung cancer
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：77
• 期：2
• 页码：393-404
• 全文大小：2,502 KB
• 参考文献：1.Heron M (2012) Deaths: leading causes for 2008. National vital statistics reports: From the Centers for Disease Control and Prevention, National Center for Health Statistics. National vital statistics. System 60(6):1–94
  2.Durate RL, Paschoal ME (2006) Molecular marker in lung cancer: prognostic role and relationship to smoking. J Bras Pneumol 32(1):56–65CrossRef
  3.Mateen S, Tyagi A, Agarwal C, Singh RP, Agarwal R (2010) Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators. Mol Carcinog 49(3):247–258PubMedCentral PubMed
  4.Kars MD, Iseri OD, Gunduz U, Ural AU, Arpaci F, Molnar J (2006) Development of rational invitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 26:4559–4568PubMed
  5.Prasanna R, Harish CC (2010) Anticancer effect of a novel 2-arylidene-4,7-dimethyl indan-1-one against human breast adenocarcinoma cell line by G 2/M cell cycle arrest. Oncol Res 18(10):461–468CrossRef PubMed
  6.Fong Y, Lin YC, Wu CY, Wang HMD, Lin LL, Chou HL, Teng YN, Yuan SS, Chiu CC (2014) TheAntiproliferative and apoptotic effects of Sirtinol, a sirtuin inhibitor on human lung cancer cells by modulating Akt/β-catenin-Foxo3A axis. Sci World J Article ID 937051
  7.Wagner TD, Yang GY (2010) The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC). Curr Drug Targets 11(1):67–73CrossRef PubMed
  8.Zhang Y, Zheng S, Ngai SM, Zheng W, Li J, Chen T, Zhong X (2014) A novel selenadiazole derivative induces apoptosis in human glioma cells by dephosphorylation of AKT. Chem Pharm Bull 62(10):994–999CrossRef PubMed
  9.Cory S, Adams JM (2003) The Bcl-2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2(9):647–656CrossRef
  10.Tsujimoto Y (2003) Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 195(2):158–167CrossRef PubMed
  11.Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281(5381):1322–1326CrossRef PubMed
  12.Shimizu S, Eguchi Y, Kamiike W, Funahashi Y, Mignon A, Lacronique V, Matsuda H, Tsujimoto Y (1998) Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. Proc Natl Acad Sci USA 95(4):1455–1459PubMedCentral CrossRef PubMed
  13.Auyeung KK, Ko JK (2020) Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell. Invest New Drugs 28(1):1–13CrossRef
  14.Eswar N, Marti-Renom MA, Webb B, Madhusudhan MS, Eramian D, Shen M, Pieper U, Sali A (2006). Comparative protein structure modeling with MODELLER. Current protocols in bioinformatics, Wiley, Inc., Supplement 15, 5.6.1-5.6.30
  15.Lovell SC, Davis IW, Arendall WB III, de Bakker PIW, Word JM, Prisant MG, Richardson JC, Richardson DC (2002) Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins: structure. Funct Genet 50:437–450CrossRef
  16.Luthy R, Bowie JU, Eisenberg D (1992) Assessment of protein models with three-dimensional profiles. Nature 356(6364):83–85CrossRef PubMed
  17.Berendsen HJC, van der Spoel D, van Drunen R (1995) GROMACS: a message-passing parallel molecular dynamics implementation. Comput Phys Commun 91:43–56CrossRef
  18.Schmid N, Andreas P, Eichenberger Alexandra Choutko, SereinaRiniker Moritz Winger, Mark Alan E, Van Gunsteren WF (2011) Definition and testing of the GROMOS force-field versions 54A7 and 54B7. Eur Biophys J40:843–856CrossRef
  19.ChemSketch, version 14.01, Advanced chemistry development, Inc., Toronto, ON, Canada, www.​acdlabs.​com , 2014
  20.Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 16:2785–2791CrossRef
  21.Laskowski RA, Swindells MB (2011) LigPlot+: multiple ligand–protein interaction diagrams for drug discovery. J Chem Info Model 51:2778–2786CrossRef
  22.Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63CrossRef PubMed
  23.Belloc F, Dumain P, Boisseau MR, Jalloustre C, Reiffers J, Bernard P (1994) A flow cytometric method using Hoechst 33342 and propidium iodide for simultaneous cell cycle analysis and apoptosis determination in unfixed cells. Cytometry 17:59–65CrossRef PubMed
  24.Kars MD, Iseri OD, Gunduz U, Ural AU, Arpaci F, Molnar J (2006) Development of rational invitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 26(6B):4559–4568PubMed
  25.Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Pradip M, Pan B-S, Kotani H (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs invitro and invivo. Mol Cancer Ther 9(7):1956–1967CrossRef PubMed
  26.Yoon H, Kim DJ, Ahn EH, Gellert GC, Shay JW, Ahn CH, Lee YB (2009) Antitumor activity of a novel antisense oligonucleotide against Akt1. J Cell Biochem 108(4):832–838PubMedCentral CrossRef PubMed
  27.Stocker H (2002) Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science 295(5562):2088–2089CrossRef PubMed
  28.Knighton DR, Zheng JH, Ten Eyck LF, Ashford VA, Xuong NH, Taylor SS, Sowadski JM (1991) Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 26 (253)(5018):407–414
  29.Zeng P, Liu B, Wang Q, Fan Q, Diao JX, Tang J, Fu XQ, Sun XG (2015) Apigenin attenuates atherogenesis through Inducing macrophage apoptosis via inhibition of AKT Ser473 phosphorylation and downregulation of plasminogen activator inhibitor-2. Oxid Med Cell Longev 2015:379538. doi:10.​1155/​2015/​379538 PubMedCentral PubMed
  30.Behera B, Mishra D, Roy B, Devi KS, Narayan R, Das J, Ghosh SK, Maiti TK (2014) Abrusprecatorius agglutinin-derived peptides induce ROS-dependent mitochondrial apoptosis through JNK and Akt/P38/P53 pathways in HeLa Cells. Chem Biol Interact. pii: S0009-2797(14)00259-2. doi:10.​1016/​j.​cbi.​2014.​08.​017
  31.Zhang BG, Du T, Zang MD, Chang Q, Fan ZY3, Li JF, Yu BQ, Su LP, Li C, Yan C, Gu QL, Zhu ZG, Yan M, Liu B (2014) Androgen receptor promotes gastric cancer cell migration and invasion via AKT-phosphorylation dependent upregulation of matrix metalloproteinase 9. Oncotarget. (Epub ahead of print)
  32.Hassan M, Watari H, Almaaty AA, Ohba Y, Sakuragi N (2014) Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. Article ID 150845, 2014:23. doi:10.​1155/​2014/​150845
  33.Searle J, Lawson TA, Abott PJ, Harmon B, Kerr JFR (1994) An electron-microscope study of the mode of cell death induced by cancer chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Pathol 116:129–138CrossRef
  34.Hsu SL, Yin SC, Liu MC, Reichert U, Ho WL (1999) Involvement of cyclin-dependent kinase activities in CD437-induced apoptosis. Exp Cell Res 252(2):332–341CrossRef PubMed
  35.van Engeland M, Ramaekers FC, Schutte B, Reutelingsperger CP (1996) A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 24:131–139CrossRef PubMed
  36.Perabo FG, Landwehrs G, Frossler C, Schmidt DG, Muller SC (2009) Antiproliferative and apoptosis inducing effects of indirubin-3-monoxime in renal cell cancer cells. Urol Oncol 29(6):815–820CrossRef PubMed
  37.She QB, Chandarlapaty S, Ye Q (2008) Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. Plos One 3:e3065PubMedCentral CrossRef PubMed
  38.Kaur M, Velmurugan B, Tyagi A, Deep G, Katiyar S, Agarwal C, Agarwal R (2009) Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther 8(8):2366–2374PubMedCentral CrossRef PubMed
  39.Zhang BG, Du T, Zang MD, Chang Q, Fan ZY3, Li JF, Yu BQ, Su LP, Li C, Yan C, Gu QL, Zhu ZG, Yan M, Liu B (2014) Androgen receptor promotes gastric cancer cell migration and invasion via AKT-phosphorylation dependent upregulation of matrix metalloproteinase 9. Oncotarget. Sep 25. (Epub ahead of print)
  40.Moretti L, Li B, Kim KW, Chen H, Lu B (2010) AT-101 a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer. J Thorac Oncol 5:680–687CrossRef PubMed
  41.Agarwal C, Tyagi A, Kaur M, Agarwal R (2007) Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 28(7):1463–1470CrossRef PubMed
  42.Park SY, Shin JN, Woo HN, Piya S, Moon AR, Seo YW, Seol DW, Kim TH (2009) DOBI is cleaved by caspases during TRAIL-induced apoptotic cell death. BMB Rep 42(8):511–515CrossRef PubMed
  43.Wong BS, Hsiao YC, Lin TW, Chen KS, Chen PN, Kuo WH, Chu SC, Hsieh YS (2009) The invitro invivo apoptotic effects of Mahonia oiwakensis on human lung cancer cells. Chem Biol Interact 180(2):165–174CrossRef PubMed
  44.Lowe SW, Ruley HE, Jacks T, Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–967CrossRef PubMed
  45.DemarcqC Bunch TR, Creswelt D, Eastman A (1994) The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ 1994(5):983–993
  46.Tanel A, Averill-Bates DA (2007) P38 and ERK mitogen-activated protein kinases mediate acrolein-induced apoptosis in Chinese hamster ovary cells. Cell Signal 19(5):968–977CrossRef PubMed
  47.Gromer S, Gross JH (2002) Methylseleninate is a substrate rather than an inhibitor of mammalian thioredoxinreductase implications for the antitumor effects of selenium. J Biol Chem 277:9701–9706CrossRef PubMed
  
• 作者单位：Prasanna Rajagopalan (1)
  Khalid A. Alahmari (2)
  Ashraf A. Elbessoumy (3)
  Meenakshisundaram Balasubramaniam (4)
  Radhakrishnan Suresh (5)
  Mohammed Eajaz Ahmed Shariff (6)
  Harish C. Chandramoorthy (7)
  
  1. Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, P.O. Box # 641, Abha, Saudi Arabia
  2. Department of Medical Rehabilitation Sciences, College of Applied Medical Sciences, King Khalid University, P.O. Box # 641, Abha, Saudi Arabia
  3. Department of Biochemistry, Faculty of Science, Alexandria University, Alexandria, Egypt
  4. Department of Geriatrics, Bioinformatics Program, University of Arkansas for Medical Sciences and University of Arkansas at Little Rock, Little Rock, AR, 72205, USA
  5. Department of Medicinal chemistry, Krisani Bioscience Pvt LTD, Hyderabad, India
  6. Department of Physiology, College of Medicine, King Khalid University, P.O.Box # 641, Abha, Saudi Arabia
  7. Department of Microbiology and Parasitology, College of Medicine, King Khalid University, P.O.Box # 641, Abha, Saudi Arabia
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Pharmacology and Toxicology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0843

文摘

Purpose Human lung cancer is contributed to be a major mortality factor in the cancer-related deaths. Arylidene indan-ones constitute a new class of potential anti-tumor compounds. Herein, we report the biological efficacy of the 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1), a potential lead molecule of arylidene indan-ones in lung cancer models. We previously described anticancer activity of FXY-1 against human breast adenocarcinoma.